UY26539A1 - DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY. - Google Patents

DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.

Info

Publication number
UY26539A1
UY26539A1 UY26539A UY26539A UY26539A1 UY 26539 A1 UY26539 A1 UY 26539A1 UY 26539 A UY26539 A UY 26539A UY 26539 A UY26539 A UY 26539A UY 26539 A1 UY26539 A1 UY 26539A1
Authority
UY
Uruguay
Prior art keywords
drospirenone
estrogen
replacement therapy
hormone replacement
active ingredient
Prior art date
Application number
UY26539A
Other languages
Spanish (es)
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to UY26539A priority Critical patent/UY26539A1/en
Publication of UY26539A1 publication Critical patent/UY26539A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica que comprende como un primer ingrediente activo un estrógeno, tal como estradiol o valerato de estradiol, en cantidades suficientes para tratar desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo ingrediente activo 6b, 7b; 15b; 16b-dimentil-3-oxo-17a-preg-4-eno-21, 17-carbolactona (drospirenona, DRSP) en cantidades suficientes para proteger el endometrio de los efectos adversos del estrógeno.A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in amounts sufficient to treat disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active ingredient 6b, 7b; 15b; 16b-dimethyl-3-oxo-17a-preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen.

UY26539A 2001-01-15 2001-01-15 DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY. UY26539A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY26539A UY26539A1 (en) 2001-01-15 2001-01-15 DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26539A UY26539A1 (en) 2001-01-15 2001-01-15 DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.

Publications (1)

Publication Number Publication Date
UY26539A1 true UY26539A1 (en) 2001-08-27

Family

ID=38812317

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26539A UY26539A1 (en) 2001-01-15 2001-01-15 DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.

Country Status (1)

Country Link
UY (1) UY26539A1 (en)

Similar Documents

Publication Publication Date Title
ME00292B (en) Drospirenone for hormone replacement therapy
IL149448A0 (en) New topical estrogen-progestogen compositions with a systemic effect
NI201000184A (en) COMPOSITIONS AND METHODS TO TREAT BREAST CANCER.
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
PE20211588A1 (en) COMPOUNDS AND THEIR USES TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
PE20060275A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROGESTIN AND ESTROGEN FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER
ES2173945T3 (en) USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MIOCARDIAC FIBROSIS.
AR080912A1 (en) ORAL SOLID DOSAGE FORMS WITH VERY LOW DOSE FOR HRT
AR032204A1 (en) CYCLODEXTRINE-DROSPIRENONE INCLUSION COMPLEXES
WO2006007312A3 (en) Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation
PE20040068A1 (en) ETONOGESTREL DECANOATE, UNDECANOATE AND DODECANOATE
PT1526856E (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
UY26539A1 (en) DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.
AR036970A1 (en) ANDROGENIC PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DEPRESSION
PE20011005A1 (en) COMBINATIONS OF A PHOSPHODIESTERASE 4 INHIBITOR AND A STEROID ANTI-INFLAMMATORY FOR THE TREATMENT OF PULMONARY DISEASES
MX2019014677A (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases.
AR043013A1 (en) PHARMACEUTICAL COMPOSITION INTENDED FOR THE TREATMENT OF ENDOMETRIOSIS
AR035633A1 (en) DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY
WO2003084521A3 (en) Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
AR048355A1 (en) ASSOCIATION BETWEEN A HETEROCICLICAL COMPOUND AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR025456A1 (en) MESOPROGESTINES (PROGESTERONE RECEIVER MODULATORS) AS COMPONENTS OF COMPOSITIONS USED FOR HORMONAL REPLACEMENT THERAPY (HRT)
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
ECSP993091A (en) CONTRACEPTIVE REGIME OF THE "PROGESTAGEN ONLY" TYPE WHICH ALLOWS A GOOD CONTROL OF THE CYCLE AND CONTRACEPTIVE EFFECTIVENESS, WHERE THE PROGESTAGEN IS SUPPLIED IN TWO PHASES
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
AR002283A1 (en) COMPOSITIONS FOR INJECTION ONCE A MONTH, WHICH CONSTITUTES A CONTRACEPTIVE MEDICATION OF PROLONGED ACTION, SUITABLE FOR THERAPY OF REPLACEMENT OF HORMONES IN PERIMENOPAUSIC AND PREMONOPAUSIC WOMEN.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20180405